BRAF and melanoma: For example, vemurafenib (a BRAF inhibitor) is an effective cytostatic drug used in the treatment of melanoma (due to frequent BRAF V600E mutations, detected in about 40% of patients), however, resistance is observed after 6–10 months of therapy, and the therapy itself is associated with side effects, including joint pain, headache, fatigue and fever.